Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis

Skin Pharmacology and Physiology

Volumn 21, Issue 4, 2008, Pages 203-210

  Schafer Korting M ^a   Schoellmann, C ^b   Korting, H C ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Fungicidal activity; Reservoir effect; Short term therapy; Terbinafine; Tinea pedis; Topical therapy

Indexed keywords

BIFONAZOLE; CICLOPIROXOLAMINE; CLOTRIMAZOLE; FLUCONAZOLE; GLUCOCORTICOID; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; LAMISIL ONCE; LAMISIL PEDISAN ONCE; MICONAZOLE; OXICONAZOLE; PLACEBO; PYRROLE DERIVATIVE; TERBINAFINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; FUNGICIDAL ACTIVITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TINEA PEDIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; NAPHTHALENES; SKIN ABSORPTION; TINEA PEDIS;

EID: 47249144679     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000135636     Document Type: Review

References (64)

1. Evans EG: Tinea pedis: clinical experience and efficacy of short treatment. Dermatology 1997;194(suppl 1):3-6.
2. Birnbaum JE: Pharmacology of the allylamines. J Am Acad Dermatol 1990;23:782-785.
3. Aste N, Pau M, Aste N, Biggio P: Tinea pedis observed in Cagliari, Italy, between 1996 and 2000. Mycoses 2003;46:38-41.
4. Kemna ME, Elewski BE: A US epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 1996;35:539-542.
5. Maruyama R, Hiruma M, Yamauchi K, Teraguchi S, Yamaguchi: An epidemiological and clinical study of untreated patients with tinea pedis within a company in Japan. Mycoses 2003;46:208-212.
6. Summerbell RC, Kane J, Krajden S: Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 1989;32:609-619.
7. McClellan KJ, Wiseman LR, Markham A: Terbinafine: an update of its use in superficial mycoses. Drugs 1999;58:179-202.
8. Schmid-Wendtner M-H: Terbinafin. Systemische und topische Therapie von Pilzinfektionen; in Schäfer-Korting M (ed): The Critical Drug Monograph. Berlin, ABW Wissenschaftsverlag, 2006.
9. Korting HC, Ollert M, Abeck D; German Collaborative Dermatophyte Drug Susceptibility Study Group: Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995;39:1206-1208.
10. Ryder N, Favre B: Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997;8:275-287.
11. Schuster I, Schaude M, Schatz F, Mieth H: Preclinical Characteristics of allylamins; in Berg D, Plempel M (eds): Sterol Biosynthesis Inhibitors. Pharmaceutical and Agrochemical Aspects. Chichester, Ellis Horwood, 1988, pp 449-470.
12. Clayton YM: Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994;130(suppl 43):7-8.
13. Korting HC, Kresimon J, Rychlik R: Comparative evaluation of the activity and clinical effectiveness of terbinafine and bifonazole preparations in the treatment of pedal mycosis. Akt Dermatol 2004;30:210-217.
14. Berman B, Ellis C, Leyden J, Lowe N, Savin R, Shupack J, Stiller M, Tschen E, Zaias N, Birnbaum JE: Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis: results of placebo-controlled, double-blind, multicenter trials. J Am Acad Dermatol 1992;26:956-960.
15. Evans EG, James IG, Joshipura RC: Two-week treatment of tinea pedis with terbinafine (Lamisil) 1% cream: a placebo-controlled study. J Dermatolog Treat 1991;2:95-97.
16. Korting HC, Tietz HJ, Bräutigam M, Mayser P, Rapatz G, Paul C; LAS-INT-06 Study Group: One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle-controlled study. Med Mycol 2001;39:335-340.
17. Lebwohl M, Elewski B, Eisen D, Savin RC: Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris. Cutis 2001;67:261-266.
18. Savin R: Treatment of chronic tinea pedis (athlete's foot type) with topical terbinafine. J Am Acad Dermatol 1990;23:786-789
19. Savin R, Atton AV, Bergstresser PR, Elewski B, Jones HE, Levine N, Leyden J, Monroe A, Pandya A, Shupack J: Efficacy of terbinafine 1% cream in the treatment of moccasin-type tinea pedis: results of placebo-controlled multicenter trials. J Am Acad Dermatol 1994;30:663-667.
20. Hollmen KA, Kinnunen T, Kiistala U, Väänänen A, Saarelainen IO, de Cuyper C, Decroix J, Broeckx W, Karvonen J: Efficacy and tolerability of terbinafine 1% emulsion gel in patients with tinea pedis. J Eur Acad Dermatol Venerol 2002;16:87-88.
21. Smith EB, Noppakun N, Newton RC: A clinical trial of topical terbinafine (a new allylamine antifungal) in the treatment of tinea pedis. J Am Acad Dermatol 1990;23:790-794.
22. Korting HC, Rychlik R, Pfeil B: Treatment of interdigital tinea pedis. Dtsch Med Wochenschr 2003;128:1819-1824.
23. Hart R, Bee-Syer SEM, Crawford F, Torgerson DJ, Young P, Russell I: Systematic review of topical treatments for fungal infections of the skin and nails of the feet. BMJ 1999;319:79-82.
24. Wahid Z, Butt J, Nishtar R: Multicentre double-blind study of efficacy and safety of terbinafine 1% cream compared with bifonazole 1% cream in patients with tinea pedis moccasin type. J Dermatolog Treat 1997;8:225-227.
25. Ablon G, Rosen T, Spedale J: Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol 1996;35:591-593.
26. Bergstresser PR, Elewski B, Hanifin J, Lesher J, Savin R, Shupack J, Stiller M, Tschen E, Zaias N, Birnbaum JE: Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4-week treatment regimens. J Am Acad Dermatol 1993;28:648-651.
27. Evans EG, Dodman B, Williamson DM, Brown GJ, Bowen RG: Comparison of terbinafine and clotrimazole in treating tinea pedis. BMJ 1993;307:645-647.
28. Patel A, Brookman SD, Bullen MU, Marley J, Ellis DH, Williams T, Barnetson RS: Topical treatment of interdigital tinea pedis: terbinafine compared with clotrimazole. Aust J Dermatol 1999;40:197-200.
29. Vermeer BJ, Staats CCG, van Houwelingen JC: Terbinafine versus Miconazol bij patienten met tinea pedis. Ned Tijdschr Geneeskd 1996;31:1605-1608.
30. Schopf R, Hettler O, Bräutigam M, et al: Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: a randomized, double-blind, multi-centre, 8-week clinical trial. Mycoses 1999;42:415-420.
31. Leenutaphong V, Tangwiwat S, Muanprasat C, Niumpradit N, Sritaveesuwan R: Double-blind study of the efficacy of 1 week topical terbinafine cream compared to 4 weeks miconazole cream in patients with tinea pedis. J Med Assoc Thai 1999;82:1006-1010.
32. Sanchez Carazo JL, Fuente C, Oliver V, Umbert P: Estudio Miconazol crema al 1% en aplicación única diaria en tiña pedis. Actas Dermosifiliogr 1994;85:388-394.
33. Chauvin MF, Viguié-Vallanet C, Kienzler JL, Larnier C: Novel, single-dose, topical treatment of tinea pedis using terbinafine: results of a dose-finding clinical trial. Mycoses 2008;51:1-6.
34. Ortonne JP, Korting HC, Viguié-Vallanet C, Larnier C, Savaluny E: Efficacy and Safety of a novel single-dose topical terbinafine formulation in patients with tinea pedis (athlete's foot): a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venerol 2006;20:1307-1313.
35. Korting HC, Kiencke P, Rychlik R: Terbinafine for the topical treatment of tinea pedis: meta-analysis of published RCT: efficacy and safety. Poster presentation, 15th Congr Eur Acad Dermatol Venereol, Rhodes, October 4-8, 2006.
36. Kienzler J-L, Queille-Roussel C, Mugglestone C, Ortonne J-P, Larnier C: Skin pharmacokinetics of the antifungal drug, terbinafine, in a novel formulation called film forming solution (FFS), for a single-dose application in dermatophytoses. Curr Med Res Opin 2007;6:1293-1302.
37. Savin RC, Zaias N: Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial. J Am Acad Dermatol 1990;23:804-807.
38. Faergemann J, Zehender H, Denouel J, Millerioux L: Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993;73:305-309.
39. Faergemann J, Zehender H, Jones T, Maibach I: Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol 1991;71:322-326.
40. Finlay AY: Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992;126(suppl 39):28-32.
41. Hill S, Thomas R, Smith SG, Finlay AY: An investigation of the pharmacokinetics of topical terbinafine (Lamisil) 1% cream. Br J Dermatol 1992;127:396-400.
42. Hosseini-Yeganeh M, McLachlan AJ: Tissue distribution of terbinafine in rats. J Pharm Sci 2001;90:1817-1828.
43. Hosseini-Yeganeh M, McLachlan AJ: Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob Agents Chemother 2002;46:2219-2228.
44. Uchida K, Yamaguchi H: Studies on the affinity of terbinafine with keratin. Jpn J Med Mycol 1993;34:207-212.
45. Tanuma H, Doi M, Ohta Y, Nishiyama S, Katsuoka K, Kaneko S, Mukai H, Abe M: Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. Mycoses 2000;43:417-432.
46. Dykes PJ, Thomas R, Lever L, Marks R: Pharmacokinetics of topically applied terbinafine: results from studies in healthy volunteer subjects and patients with pityriasis versicolor. J Dermatolog Treat 1990;1:19-21.
47. Surber C, Schwarb FP, Smith EW: Tape-stripping technique. J Toxicol Cutaneous Ocul Toxicol 2001;20:461-474.
48. Lücker PW, Beubler E, Kukovetz WR, Ritter W: Retention time and concentration in human skin bifonazole and clotrimazole. Dermatologica 1984;169(suppl 1):51-56.
49. Finnin BC, Morgan TM: Transdermal penetration enhancers: applications, limitations, and potential. J Pharm Sci 1999;88:955-958.
50. Alberti I, Kalia YN, Naik A, Bonny JD, Guy RH: In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum. J Control Release 2001;7:319-327.
51. Alberti I, Kalia YN, Naik A, Guy RH: Assessment and prediction of the cutaneous bioavailability of topical terbinafine in vivo in man. Pharm Res 2001;18:1472-1475.
52. Monti D, Saccomani L, Chetoni P, Burgalassi S, Saettone MF, Mailland F: In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm 2005;31:11-17.
53. Ritter W, Siefert HM: Biological disposition and percutaneous absorption of bifonazole in animals and man; in Fromtling RA (ed): Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona, Prous Science Publishers, 1987, pp 383-405.
54. Sobue S, Sekiguchi K, Nabeshima T: Intracutaneous distribution of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum. Antimicrob Agents Chemother 2004;48:216-223.
55. Pershing LK, Corlett J, Jorgensen C: In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. Antimicrob Agents Chemother 1994;38:90-95.
56. Faergemann J: Pharmacokinetics of terbinafine. Rev Contemp Pharmacother 1997;8:289-297.
57. Patschke K, Wegner LA, Oberste-Lehn H, Horster FA: Pharmakokinetische Untersuchungen nach topischer Anwendung von Clotrimazol (Canesten). Münch Med Wochenschr 1976;118(suppl 1):12-15.
58. Degreef H, Heeres J, Borgers M: Antifungal azoles for skin disorders. Expert Opin Ther Pat 2006;16:1235-1253.
59. Klimke K, Schäfer-Korting M: Einfluss von Keratin auf die Wirksamkeit von Fluconazol. Mycoses 1997;40(suppl 1):43-46.
60. Tomura A, Takahashi S: Experimental study on pharmacokinetic action of topical antifungal agents in the human stratum corneum. Jpn J Med Mycol 1995;36:149-156.
61. Haneke E: Retention of ketoconazole in the skin following oral treatment. Hautarzt 1987;38:93-96.
62. Faergemann J, Laufen H: Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once weekly. Acta Derm Venereol 1996;76:219-221.
63. Kawada A, Aragane Y, Tezuka T: Clinical and pharmacokinetic studies of continuous itraconazole for the treatment of onychomycosis. J Dermatol 2004;31:104-108.
64. Leyden J: Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol 1998;38:S42-S47.